Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY: TKI De-escalation and Stopping in CML
NCT01804985Phase 2Completed
- Sponsor
- University of Liverpool
- Start
- Dec 2013
- Primary completion
- Jun 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib, nilotinib and dasatinib in chronic myeloid leukemia (CML), sponsored by University of Liverpool. Primary endpoint: Proportion of patients who can first de-escalate their treatment and then stop treatment completely without losing MMR at 37 months. Started Dec 2013; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01804985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01804985.